Manuscript received May 9, 1994; accepted July 7, 1994. Address correspondence and reprint requests to Dr. Jeanine M. Walenga, Department of Pathology, Loyola University Med ical Center, 2160 South First Avenue, Maywood, IL 60153, U.S.A. Summary: Invasive cardiac procedures and cardiac sur gery, which have become a significant component of health care, provide a particular case scenario where there are special considerations given to control bleeding and to have available alternative anticoagulants for pa tients unable to tolerate heparin (e.g., heparin-induced thrombocytopenia). We describe a comprehensive proto col for blood preservation in cardiac surgery incorporat ing the patient's medical history, autologous transfusions, and intraoperative techniques of heparin and protamine titration and dosing. Furthermore, various new anticoag ulants under clinical development are discussed, particu larly hirudin, hirulog, iloprost, ancrod, Lomoparan, low- molecular-weight heparins, 1-deamino-8-D-arginine- vasopressin (DDAVP), and aprotinin. These approaches should benefit the patient with difficult to control periop erative bleeding, heparin-induced thrombocytopenia, al lergic reactions to protamine, platelet dysfunction, and poor response to heparin (e.g., due to antithrombin III deficiency).
Green D.Heparin-induced thrombocytopenia. Med J Aust1986;44:HS37.
2.
Olinger GN, Hussey CV, Olive JA, et al. Cardiopulmonary bypass for patients with previously documented heparin induced platelet aggregation. J Thorac Cardiovasc Surg1984; 87:673.
3.
Pifarre R., Babka R., Sullivan HJ, et al. Management of postoperative heparin rebound following cardiopulmonary bypass. J Thorac Cardiovasc Surg1981;81(3):378.
4.
Levy JH, Zaidan JR, Faraj B.Prospective evaluation of risk of protamine reactions in patients with NPH insulin-dependent diabetes. Anesth Analg1986 ;65:739.
5.
Bidstrup BP, Royston D., Sapsford RN, et al. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg1989;97:364.
6.
Dietrich W., Spannagl M., Jochum M., et al. Influence of highdose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology1990;73:1119.
7.
Havel T., Teufelsbauer H., Knöbl P., et al. Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation. J Thorac Cardiovasc Surg1991;101:968.
8.
Pineo GF, Raskob GE, Hull RD, et al. Autologous blood transfusion: what are the advantages? [Abstract 756]. In Proceedings of the International Society of Hematology 24th Congress. London: Blackwell, 1992:197.
9.
Murphy P., Heal JM, Blumberg N.Infection or suspected infection after hip replacement surgery with autologous or homologous blood transfusions. Transfusion1991;31:212.
10.
Mummaneni N. , Istanbouli M., Pifarre R., et al. Increased heparin requirements with autotransfusion. J Thorac Cardiovasc Surg1983;86:446.
11.
Babka R., Colby C., El Etr A., et al. Monitoring of intraoperative heparinization and blood loss following cardiopulmonary bypass surgery. J Thorac Cardiovasc Surg1977;73:780.
12.
Cole CW, Bormanis J.Ancrod: a practical alternative to heparin. J Vasc Surg1988;8(1):59.
13.
Demers C., Ginsberg JS, Brill-Edwards P., et al. Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia . Blood1991 ;78(9):2194.
14.
Bell WR, Bolton G., Pitney WRThe effect of arvin on blood coagulation factors. Br J Haematol1968;15:589.
15.
Regoeczi E. , Bell WRIn-vivo behaviour of the coagulant enzyme from Agkistrodon rhodostoma venum: studies using131/Arvin therapy. Br J Haematol1969;156:573.
16.
Sharp AA, Warren BA, Paxton AM, et al. Anticoagulant therapy with a purified fraction of Malayan pit viper venom. Lancet1968;1:493.
17.
Davies JA, Merrich MV, Sharp AA, et al. Controlled trial of ancrod and heparin in the treatment of deep-vein thrombosis of lower limb. Lancet1972;1:113.
18.
Latello ZSRetrospective study of complications and adverse effects of treatment with thrombin-like enzymes: a multicentre trail. Thromb Haemost1983;50:604.
Pitney WR, Holt Pjl, Bray C., et al. Acquired resistance to treatment with Arvin. Lancet1969 ;1:79.
21.
Aviado DM, Porter JMPentoxifylline: a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects . Pharmacotherapy1984;4(6):297.
22.
Kappa JR, Horn MK, Fisher CA, et al. Efficacy of iloprost (ZK 36374) versus aspirin in preventing heparin-induced platelet activation during cardiac operations. J Thorac Cardiovasc Surg1987;94:405.
23.
Sinzinger H. , O'Grady J., Fitscha P., et al. Comparable effect of prostaglandin E 1 in decreasing in vivo platelet deposition on human lesion sites after intravenous and intraarterial application. Thromb Res1988;50:749.
24.
Kappa JR, Fisher CA, Todd B., et al. Intraoperative management of patients with heparin-induced thrombocytopenia . Ann Thorac Surg1990;49:714.
25.
Casu B.Structure of heparins and their fragments. Nouv Rev Fr Hematol1984;26:211.
26.
Fareed J., Walenga JM, Hoppensteadt D., et al. Chemical and biological heterogeneity in low molecular weight heparins: implications for clinical use and standardization. Semin Thromb Haemost1989;15(4):440.
Thomas DPPrevention of post-operative thrombosis by low molecular weight heparin in patients undergoing hip replacement. Thromb Haemost1992;67(5):491.
29.
Ortel TL, Gockerman JP, Califf RM, et al. Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis. Thromb Haemost1992;67(3):292.
30.
Gouault-Heillmann M., Huft Y., Contant G., et al. Cardiopulmonary bypass with low molecular weight heparin fraction. Lancet1983;11:1374.
31.
Massonnet-Castel S., Pelissier E., Dreyfus G., et al. Low-molecular-weight heparin in extracorporeal circulation. Lancet1984;1(8387):1182.
32.
Robitaille D., Leclerc JR, Laberge R., et al. Cardiopulmonary bypass with a low-molecular-weight heparin fraction (Enoxaparin) in a patient with a history of heparin-associated thrombocytopenia. J Thorac Cardiovasc Surg1992;103(3): 597.
33.
Roussi JH, Houbouyen LL, Goguel AFUse of low molecular weight heparin in heparin-induced thrombocytopenia with thrombotic complications. Lancet1984;1:1183.
34.
Eichinger S. , Kyrle PA, Brenner B., et al. Thrombocytopenia associated with low-molecular-weight heparin. Lancet1991; 337:1425.
35.
Massonnet-Castel S., Pelissier E., Bara L., et al. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. Haemostasis1986;16:139.
36.
Vitoux JF, Mathieu JF, Roncato M., et al. Heparin associated thrombocytopenia treatment with low molecular weight heparin. Thromb Haemost1986;55:37.
37.
Bajusz S., Barabas E., Tolnay P., et al. Inhibition of thrombin and trypsin by tripeptide aldehyde. Int J Peptide Protein Res1978;12:217.
38.
Kettner C., Mersinger L., Knabb R.The selective inhibition of thrombin by peptides of boroarginine. J Biol Chem1990; 265(30):18289.
39.
Markwardt F. , Fink G., Kaiser B., et al. Pharmacological survey of recombinant hirudin. Pharmazie1988;43:202.
40.
Okamoto S., Hijikata A., Ikezawa K., et al. A new series of synthetic thrombin inhibitors (OM-inhibitors) having extremely potent and selective action. Thromb Res1976;8 (suppl II):77.
41.
Chomiak PN, Walenga JM, Koza MJ, et al. Investigation of a thrombin inhibitor peptide as an alternative to heparin in cardiopulmonary bypass surgery. Circulation1993;88[part 2]:407.
42.
Walenga JM, Bakhos M., Messmore HL, et al. Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass model. Ann Thorac Surg1991;51:271.
43.
Salzman EW, Weinstein MJ, Reilly D., et al. Adventures in hemostasis: desmopressin in cardiac surgery. Arch Surg1993;128:212.
44.
Hackmann T. , Gascoyne RD, Naiman SC, et al. A trial of desmopressin (1-desamino-8-D-arginine vasopressin) to reduce blood loss in uncomplicated cardiac surgery. N Engl J Med1989;321:1437.
45.
Seear MD, Wadsworth LD, Rogers PC, et al. The effect of desmopressin acetate (DDAVP) on postoperative blood loss after cardiac operations in children. J Thorac Cardiovasc Surg1989;98:217.
46.
Bick RLClinical relevance of antithrombin III. Semin Thromb Haemost1982;8(4):276.
